HDR Prostate Brachytherapy.

Brachytherapy has become an essential pillar in all-stages of localized prostate cancer, where dose escalation has been demonstrated to improve outcome. HDR brachytherapy has evolved over the decades to be administered in 1-2 fractions. As either monotherapy or in combination with external beam, it offers many advantages over other treatment alternatives. Precise control over dose delivery allows focal dose escalation while sculpting dose around critical organs to maintain excellent tolerance. The high dose per fraction exploits the low α/β ratio of prostate cancer and triggers transcriptional changes in the tumor genome enhancing radiation sensitivity. We review the development, patient selection and results, and describe in detail the techniques for HDR brachytherapy.

[1]  T. Pugh,et al.  Magnetic resonance imaging-based treatment planning for prostate brachytherapy. , 2013, Brachytherapy.

[2]  Peter Bownes,et al.  High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  A novel method for accurate needle-tip identification in trans-rectal ultrasound-based high-dose-rate prostate brachytherapy. , 2011, Brachytherapy.

[4]  É. Vigneault,et al.  High-dose-rate brachytherapy boost for prostate cancer treatment: Different combinations of hypofractionated regimens and clinical outcomes. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  M. Kattan,et al.  High‐dose rate brachytherapy compared with open radical prostatectomy for the treatment of high‐risk prostate cancer: 10 year biochemical freedom from relapse , 2012, BJU international.

[6]  M. Chatfield,et al.  HDR brachytherapy combined with external beam radiation for localised prostate cancer: Early experience from the Sydney Cancer Centre , 2012, Journal of medical imaging and radiation oncology.

[7]  Deidre Batchelar,et al.  A phantom study to assess accuracy of needle identification in real-time planning of ultrasound-guided high-dose-rate prostate implants. , 2013, Brachytherapy.

[8]  Howard Pai,et al.  Population‐based 10‐year oncologic outcomes after low‐dose‐rate brachytherapy for low‐risk and intermediate‐risk prostate cancer , 2013, Cancer.

[9]  Juan Cardenal,et al.  High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: Toxicity and long-term biochemical results. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  R. Galalae,et al.  The 15-year outcomes of high-dose-rate brachytherapy for radical dose escalation in patients with prostate cancer - a benchmark for high-tech external beam radiotherapy alone? , 2014, Brachytherapy.

[11]  Hong Ye,et al.  Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer. , 2016, International journal of radiation oncology, biology, physics.

[12]  H. Samaratunga,et al.  Long‐term outcomes of high‐dose‐rate brachytherapy for intermediate‐ and high‐risk prostate cancer with a median follow‐up of 10 years , 2017, BJU international.

[13]  P. Prada,et al.  Biochemical outcome after high‐dose‐rate intensity modulated brachytherapy with external beam radiotherapy: 12 years of experience , 2012, BJU international.

[14]  Daniel W. Miller,et al.  Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.

[15]  P. Hoskin,et al.  Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  Dimos Baltas,et al.  High dose rate brachytherapy as monotherapy for localised prostate cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  F. Vicini,et al.  Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. , 2011, International journal of radiation oncology, biology, physics.

[18]  A. D'Amico,et al.  Long‐term outcomes of partial prostate treatment with magnetic resonance imaging‐guided brachytherapy for patients with favorable‐risk prostate cancer , 2018, Cancer.

[19]  C. Kirisits,et al.  Review of clinical brachytherapy uncertainties: Analysis guidelines of GEC-ESTRO and the AAPM☆ , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  B. Carey,et al.  Multi-parametric MRI-guided focal tumor boost using HDR prostate brachytherapy: a feasibility study. , 2014, Brachytherapy.

[21]  H. Patrocinio,et al.  Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiation therapy in the treatment of intermediate-risk prostate cancer - long term results. , 2012, International journal of radiation oncology, biology, physics.

[22]  J. Praag,et al.  High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-year experience. , 2012, International journal of radiation oncology, biology, physics.

[23]  J. Millar,et al.  Urethral strictures following high-dose-rate brachytherapy for prostate cancer: analysis of risk factors. , 2013, Brachytherapy.

[24]  M. Steinberg,et al.  High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results. , 2016, International journal of radiation oncology, biology, physics.

[25]  Hans T. Chung,et al.  Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy. , 2017, Brachytherapy.

[26]  G. Morton,et al.  High dose-rate brachytherapy in the treatment of prostate cancer , 2018, Translational andrology and urology.

[27]  Joos V Lebesque,et al.  Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Mate,et al.  High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. , 1998, International journal of radiation oncology, biology, physics.

[29]  M. Parmar,et al.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.

[30]  R. Pötter,et al.  GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  Daniel I Glazer,et al.  Prostate imaging reporting and data system version 2 (PI-RADS v2): a pictorial review , 2016, Abdominal Radiology.

[32]  I. Hsu,et al.  High-dose-rate brachytherapy boost for prostate cancer: comparison of two different fractionation schemes. , 2008, International journal of radiation oncology, biology, physics.

[33]  D Andrew Loblaw,et al.  Use of cone-beam imaging to correct for catheter displacement in high dose-rate prostate brachytherapy. , 2011, Brachytherapy.

[34]  J. Pérez-Gracia,et al.  Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes. , 2016, Brachytherapy.

[35]  Deidre Batchelar,et al.  Validation study of ultrasound-based high-dose-rate prostate brachytherapy planning compared with CT-based planning. , 2014, Brachytherapy.

[36]  A. Pantuck,et al.  High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer. , 2017, Brachytherapy.

[37]  D. Brenner,et al.  Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue , 2002 .

[38]  G. Gustafson,et al.  High-Dose-Rate Prostate Brachytherapy: An Excellent Accelerated-Hypofractionated Treatment for Favorable Prostate Cancer , 2010, American journal of clinical oncology.

[39]  P. Bogner,et al.  Open MR-Guided High-Dose-Rate (HDR) Prostate Brachytherapy: Feasibility and Initial Experiences Open MR-Guided High-Dose-Rate (HDR) Prostate Brachytherapy , 2011, Pathology & Oncology Research.

[40]  J. Pouliot,et al.  Measurement of craniocaudal catheter displacement between fractions in computed tomography–based high dose rate brachytherapy of prostate cancer , 2007, Journal of applied clinical medical physics.

[41]  P. Hoskin,et al.  Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[42]  S. Kariya,et al.  Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium. , 2017, Brachytherapy.

[43]  The Transcriptional Landscape of Radiation-Treated Human Prostate Cancer: Analysis of a Prospective Tissue Cohort. , 2018, International journal of radiation oncology, biology, physics.

[44]  G. Morton,et al.  High-dose-rate brachytherapy boost for prostate cancer: rationale and technique , 2014, Journal of contemporary brachytherapy.

[45]  Prevention of needle displacement in multifraction high-dose-rate prostate brachytherapy: A prospective volumetric analysis and technical considerations. , 2015, Practical radiation oncology.

[46]  T. Phan,et al.  High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. , 2007, The Journal of urology.

[47]  M. Viergever,et al.  Development and Testing of a Magnetic Resonance (MR) Conditional Afterloader for Source Tracking in Magnetic Resonance Imaging-Guided High-Dose-Rate (HDR) Brachytherapy. , 2018, International journal of radiation oncology, biology, physics.

[48]  W. J. Morris,et al.  Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cance , 2017, International journal of radiation oncology, biology, physics.

[49]  M. Milette,et al.  Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion. , 2014, Brachytherapy.

[50]  G. Pond,et al.  Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. , 2006, Brachytherapy.

[51]  P. Novaes,et al.  Updated results of high-dose rate brachytherapy and external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition. , 2008, International braz j urol : official journal of the Brazilian Society of Urology.

[52]  G. Gustafson,et al.  Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients. , 2014, Brachytherapy.

[53]  Alexandra Rink,et al.  Lessons learned using an MRI-only workflow during high-dose-rate brachytherapy for prostate cancer. , 2016, Brachytherapy.

[54]  G. Gustafson,et al.  Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. , 1995, International journal of radiation oncology, biology, physics.

[55]  J. Pouliot,et al.  American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. , 2012, Brachytherapy.

[56]  Alexandra Rink,et al.  Dosimetric feasibility of ablative dose escalated focal monotherapy with MRI-guided high-dose-rate (HDR) brachytherapy for prostate cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[57]  Baris Turkbey,et al.  Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer , 2016, CA: a cancer journal for clinicians.

[58]  Wendy L. Smith,et al.  Prostate volume contouring: a 3D analysis of segmentation using 3DTRUS, CT, and MR. , 2007, International journal of radiation oncology, biology, physics.

[59]  R. Stafford,et al.  Prostate magnetic resonance imaging for brachytherapists: Anatomy and technique. , 2017, Brachytherapy.

[60]  Á. Csomós,et al.  Needle-related ultrasound artifacts and their importance in anaesthetic practice. , 2014, British journal of anaesthesia.

[61]  R. Mark,et al.  Interstitial High Dose Rate (HDR) Brachytherapy as Monotherapy for Early Stage Prostate Cancer: Median 8 Year Results in 312 Patients , 2010 .

[62]  G. Gustafson,et al.  Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer. , 2018, International journal of radiation oncology, biology, physics.

[63]  J. Pouliot,et al.  Early clinical experience with anatomy-based inverse planning dose optimization for high-dose-rate boost of the prostate. , 2002, International journal of radiation oncology, biology, physics.

[64]  G. Morton,et al.  Intraoperative ultrasound-based planning can effectively replace postoperative CT-based planning for high-dose-rate brachytherapy for prostate cancer. , 2016, Brachytherapy.

[65]  Hans T. Chung,et al.  Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[66]  P. Hoskin,et al.  High dose rate afterloading brachytherapy for prostate cancer: catheter and gland movement between fractions. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[67]  R. Kudzia,et al.  High-dose-rate brachytherapy as a monotherapy for prostate cancer--Single-institution results of the extreme fractionation regimen. , 2015, Brachytherapy.

[68]  P. Unger,et al.  Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. , 2011, The Journal of urology.

[69]  Y. Yoshioka,et al.  High-Dose-Rate Brachytherapy as Monotherapy for Intermediate- and High-Risk Prostate Cancer: Clinical Results for a Median 8-Year Follow-Up. , 2016, International journal of radiation oncology, biology, physics.

[70]  Rick Chappell,et al.  Is α/β for prostate tumors really low? , 2001 .

[71]  P. Carroll,et al.  Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. , 2012, International journal of radiation oncology, biology, physics.

[72]  Liying Zhang,et al.  Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer. , 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

[73]  P. Ágoston,et al.  Moderate dose escalation with single-fraction high-dose-rate brachytherapy boost for clinically localized intermediate- and high-risk prostate cancer: 5-year outcome of the first 100 consecutively treated patients. , 2011, Brachytherapy.

[74]  S. van Dyk,et al.  Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer. , 2013, International journal of radiation oncology, biology, physics.

[75]  Hans T. Chung,et al.  High dose-rate brachytherapy boost for intermediate risk prostate cancer: Long-term outcomes of two different treatment schedules and early biochemical predictors of success. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[76]  Y. Yamada,et al.  Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. , 2008, Brachytherapy.

[77]  J. Williamson,et al.  Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. , 2004 .

[78]  A. Kishan,et al.  Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. , 2017, European urology.

[79]  J. Logue,et al.  A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[80]  J. Millar,et al.  High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer. , 2010, Brachytherapy.

[81]  Blasko,et al.  Brachytherapy and Organ Preservation in the Management of Carcinoma of the Prostate. , 1993, Seminars in radiation oncology.

[82]  P. Hoskin,et al.  GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[83]  Dimos Baltas,et al.  High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. , 2013, International journal of radiation oncology, biology, physics.

[84]  Y. Yamada,et al.  Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer. , 2013, Brachytherapy.

[85]  Kari Tanderup,et al.  Learning curve of MRI-based planning for high-dose-rate brachytherapy for prostate cancer. , 2016, Brachytherapy.

[86]  Lei Dong,et al.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[87]  Frank-André Siebert,et al.  Imaging of implant needles for real-time HDR-brachytherapy prostate treatment using biplane ultrasound transducers. , 2009, Medical physics.

[88]  J. Chin,et al.  Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.